Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D-enhanced intralymphatic immunotherapy versus placebo and comparison with SLIT in grass pollen allergic rhinitis
2024-515271-35-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Feb 2023
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of alutard phleum pratense, cholecalciferol and phleum pratense allergen extract in allergic rhinitis (AR) (4 arms), sponsored by Karolinska University Hospital. Primary endpoint: Combined Symptom Medication Score during grass pollen season after treatment. Planned start Feb 2023; status: authorised.
02
Drugs
alutard phleum pratensecholecalciferolphleum pratense allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2024-515271-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515271-35-00.